At the 1,000-square-meter dual exhibition booths in the Medical Devices & Healthcare Pavilion and the Biomedical Special Zone, Bristol-Myers Squibb will comprehensively present its "China 2030 Strategy" through ingeniously designed 3D naked-eye and augmented reality (AR) technologies, showcasing over 15 innovative products and R&D pipelines across core therapeutic areas such as oncology, hematology, and immunology. Several of these products or pipelines have the potential to become "first-in-class" or "best-in-class" in their respective fields, including a highly promising LAG-3 immune checkpoint inhibitor in oncology, a prominent CAR-T cell therapy in hematology, and a TYK2 inhibitor in immunology that holds promise for treating various immune-mediated diseases.
Meanwhile, Bristol-Myers Squibb will also, guided by the ethos of "Openness and Sharing, Cooperation for Mutual Benefit", forge multiple strategic partnerships with government, industry, academia, and research stakeholders across the biopharmaceutical ecosystem, aiming to advance industry development, patient services, and academic research, thereby fulfilling its corporate vision of "Leading Science, Transforming Patients' Lives" and contributing to the "Healthy China 2030" initiative.
